Dimiati Herlina, Umara Dimas Arya, Naufal Iflan
Department of Pediatric, Universitas Syiah Kuala, Banda Aceh, Aceh, Indonesia, Indonesia.
Department of Cardiology, Universitas Syiah Kuala, Banda Aceh, Aceh, Indonesia, Indonesia.
F1000Res. 2022 Sep 12;10:792. doi: 10.12688/f1000research.53966.2. eCollection 2021.
Respiratory tract infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) first occurred in Wuhan, China, in December 2019 and was declared as a pandemic by WHO. The interaction between the 2019 coronavirus disease (COVID-19) and pulmonary hypertension (PH) in children is not widely known. Phosphodiesterase-5 inhibitors (PDEI), one class of drugs used to treat PH, including sildenafil, can suppress angiotensin type I (AT-1) receptor expression. Furthermore, it reduces proinflammatory cytokines and infiltrates the alveolar, inhibits endothelial and smooth muscle transition, mesenchymal cells in the pulmonary artery, and prevents clotting and thrombosis complications. Sildenafil has shown positive effects by diverting the blood flow to the lungs in such a way that ventilation is adequate and can also be anti-inflammatory.
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）引起的呼吸道感染于2019年12月在中国武汉首次出现，并被世界卫生组织宣布为大流行病。2019冠状病毒病（COVID-19）与儿童肺动脉高压（PH）之间的相互作用尚不广为人知。磷酸二酯酶-5抑制剂（PDEI）是一类用于治疗PH的药物，包括西地那非，可抑制血管紧张素I（AT-1）受体表达。此外，它可减少促炎细胞因子并浸润肺泡，抑制肺动脉内皮和平滑肌转变、间充质细胞，并预防凝血和血栓形成并发症。西地那非通过以一种通气充足的方式将血流转向肺部而显示出积极效果，并且还具有抗炎作用。
